Acute tumour response to the MEK1|[sol]|2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI

M Beloueche-Babari; Y Jamin; V Arunan; S Walker-Samuel; M Revill; P D Smith; J Halliday; J C Waterton; H Barjat; P Workman; M O Leach; S P Robinson

首页> 外文期刊>British Journal of Cancer >Acute tumour response to the MEK1|[sol]|2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI

【24h】

Acute tumour response to the MEK1|[sol]|2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI

机译：通过非侵入性扩散加权MRI评价对MEK1 | [sol] | 2抑制剂selumetinib（AZD6244，ARRY-142886）的急性肿瘤反应

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Background:Non-invasive imaging biomarkers underpin the development of molecularly targeted anti-cancer drugs. This study evaluates tumour apparent diffusion coefficient (ADC), measured by diffusion-weighted magnetic resonance imaging (DW-MRI), as a biomarker of response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in human tumour xenografts.

机译：背景：无创成像生物标志物支持分子靶向抗癌药物的开发。这项研究评估了通过扩散加权磁共振成像（DW-MRI）测量的肿瘤表观扩散系数（ADC），作为对人肿瘤异种移植物中MEK1 / 2抑制剂selumetinib（AZD6244，ARRY-142886）的反应的生物标志物。

著录项

来源
《British Journal of Cancer》 |2013年第6期|共8页
作者
M Beloueche-Babari; Y Jamin; V Arunan; S Walker-Samuel; M Revill; P D Smith; J Halliday; J C Waterton; H Barjat; P Workman; M O Leach; S P Robinson;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. The MEK1|[sol]|2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models [J] . S V Holt, A Logié, R Odedra, British Journal of Cancer . 2012,第5期

机译：MEK1 | [sol] | 2抑制剂selumetinib（AZD6244; ARRY-142886）在人肿瘤异种移植模型中与常规化学治疗剂联合使用时可增强抗肿瘤功效
2. The MEK1|[sol]|2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models [J] . S V Holt, A Logié, R Odedra, British Journal of Cancer . 2012,第5期

机译：MEK1 | [sol] | 2抑制剂selumetinib（AZD6244; ARRY-142886）在人肿瘤异种移植模型中与常规化学治疗剂联合使用时可增强抗肿瘤功效
3. A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma [J] . Holkova Beata, Zingone Adriana, Kmieciak Maciej, Clinical cancer research: an official journal of the American Association for Cancer Research . 2016,第5期

机译：口服MEK1 / 2抑制剂AZD6244（Selumetinib，ARRY-142886）在复发/难治性多发性骨髓瘤中的II期试验
4. Non-invasive method for differentiating malignant and benign tumours, by the optimization of visual demonstration of MRI scans, using virtual instrument [C] . Lakshmi /A/. Pavani IEEE Global Conference on Signal and Information Processing . 2014

机译：通过使用虚拟仪器优化MRI扫描的视觉演示，区分恶性和良性肿瘤的非侵入性方法
5. Non-invasive fusion imaging for regional evaluation of obstructive lung disease using MRI and PET. [D] . Holmes, James Hartman. 2006

机译：使用MRI和PET对区域性阻塞性肺疾病进行评估的非侵入性融合成像。
6. Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244 ARRY-142886) evaluated by non-invasive diffusion-weighted MRI [O] . M Beloueche-Babari, Y Jamin, V Arunan, 2013

机译：无创扩散加权MRI对MEK1 / 2抑制剂selumetinib（AZD6244ARRY-142886）的急性肿瘤反应
7. Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI. [O] . Beloueche-Babari, M, Jamin, Y, Arunan, V, 2013

机译：通过非侵入性扩散加权mRI评估对mEK1 / 2抑制剂selumetinib（aZD6244，aRRY-142886）的急性肿瘤反应。

Acute tumour response to the MEK1|[sol]|2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅